The search for valuable cancer-related proteins
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise to help researchers analyze and understand thousands of cancer-related proteins. These proteins may be useful as therapeutic targets, early detection signals or biomarkers of cancer treatment response for a number of disease types, including lung, colon, breast, ovarian, pancreatic, prostate...
Treatment advances for CLL, the most common leukemia
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
Immunotherapy before surgery for glioblastoma shows promise
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months...
Immunotherapy advances in targeting pancreatic, prostate and kidney cancers
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology.
Sharma, along with Jim Allison, Ph.D., chair of Immunology, leads the immunotherapy platform of MD Anderson’s Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.<...
